Premium
Targeted therapy in inflammatory breast cancer
Author(s) -
Yamauchi Hideko,
Ueno Naoto T.
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25171
Subject(s) - lapatinib , medicine , inflammatory breast cancer , targeted therapy , cancer research , breast cancer , cancer , metastasis , trastuzumab , epidermal growth factor receptor , lymphangiogenesis , angiogenesis , oncology , bioinformatics , biology
Despite the introduction of multimodality treatment approaches, the prognosis of inflammatory breast cancer (IBC) is poor. Recent developments in molecular targeted therapy may be effective against IBC. The authors report the results of a literature review. Trastuzumab and lapatinib, which target human epidermal growth factor receptor 2 (HER‐2), have demonstrated benefit in clinical trials for HER‐2–positive breast cancers. WNT1‐inducible signaling pathway protein 3, Ras homolog gene family member C guanosine triphosphatase, epidermal growth factor receptor (EGFR), and p27 kip1 also have been studied as potential targets in IBC. Molecular targets in vasculolymphatic processes (angiogenesis, lymphangiogenesis, and vasculogenesis) have demonstrated greater potential in IBC than in non‐IBC. Although loss of E‐cadherin is a hallmark of epithelial‐to‐mesenchymal transition and may correlate with the promotion of metastasis, paradoxically, E‐cadherin is overexpressed in IBC through an unknown mechanism. On the basis of dissecting the molecular mechanism of the aggressiveness of IBC, the authors currently are investigating whether EGFR may aid in developing innovative targeted therapies. Cancer 2010;116(11 suppl):2758–9. © 2010 American Cancer Society.